R239
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 45
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.450
- G2M_CHECKPOINT+0.340
- FATTY_ACID_METABOLISM+0.300
- PANCREAS_BETA_CELLS+0.260
- PEROXISOME+0.260
- UNFOLDED_PROTEIN_RESPONSE+0.230
- MYC_TARGETS_V1+0.220
- PROTEIN_SECRETION+0.210
- ADIPOGENESIS+0.200
- OXIDATIVE_PHOSPHORYLATION+0.190
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.400
- ALLOGRAFT_REJECTION-0.370
- INFLAMMATORY_RESPONSE-0.320
- TGF_BETA_SIGNALING-0.320
- TNFA_SIGNALING_VIA_NFKB-0.310
- COMPLEMENT-0.290
- INTERFERON_GAMMA_RESPONSE-0.280
- PI3K_AKT_MTOR_SIGNALING-0.240
- APICAL_SURFACE-0.230
- KRAS_SIGNALING_DN-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12202421 | — | — | 0.886 |
| 2 | DRR168601 | — | — | 0.870 |
| 3 | TCGA-GV-A3QI-01A-11R-A220-07 | — | — | 0.867 |
| 4 | R150 | — | — | 0.853 |
| 5 | R55 | — | — | 0.845 |
| 6 | 20040104.LumB | — | B | 0.844 |
| 7 | SRR1797279 | — | cohortSC | 0.843 |
| 8 | SRR1516065 | — | — | 0.835 |
| 9 | ERR2208893 | — | — | 0.834 |
| 10 | SRR26320065 | — | — | 0.834 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.450 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.260 | Cobimetinib | — uncovered |
| PEROXISOME | 0.260 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.230 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.220 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.210 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.190 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.130 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.080 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.070 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.010 | Inavolisib | — uncovered |